 |
만성 C형 간염치료제 급여기준 확대 - 2016-05-01 예정 |  |
153 | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
 |
김태빈 |  |
2016-04-20 | ||||||||||||||||||||||||||||||
[629] 기타의 화학요법제
※ 관련근거 ․ Goldman-Cecil Medicine, 25e, Antivirals for Hepatitis C Virus Infections (2016) ․ Harrison's Online(19th) ․ Sleisenger and Fordtran's Gastrointestinal and Liver Disease (2016) ․ Basic & Clinical Pharmacology, 13e(2015) ․ Current Medical Diagnosis & Treatment: Chapter 16. Liver, Biliary Tract, & Pancreas Disorders, 2. Chronic Hepatitis C, Clinical Findings & Diagnosis (2015) ․ Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 8ed(2015) ․ 2013년 대한간학회: C형간염 진료 가이드 ․ EASL(European Association for the Study of the Liver) Recommendations on Treatment of Hepatitis C (2015) ․ AASLD-IDSA Recommendations for Testing, Managing, and Treating Adults Infected With Hepatitis C Virus ․ Mizokami M et al. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infect Dis. 2015 Jun;15(6):645-53. ․ Afdhal N et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014 May 15;370(20):1889-98. ․ Afdhal N et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014 Apr 17;370(16):1483-93. ․ Kowdley KV et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014 May 15;370(20):1879-88. ․ Kwang-Hyub Han, et al. A Phase 3b, Multicenter, Open-Label Study to Investigate the Efficacy Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination in Treatment-Naive and Treatment-Experienced Korean and Taiwanese Subjects with Chronic Genotype 1 HCV Infection. Study GS-US-337-0131 Interim Clinical Study Report. [629] 기타의 화학요법제
※ 관련근거 ․ Goldman-Cecil Medicine, 25e, Antivirals for Hepatitis C Virus Infections (2016) ․ Harrison's Online(19th) ․ Sleisenger and Fordtran's Gastrointestinal and Liver Disease (2016) ․ Basic & Clinical Pharmacology, 13e(2015) ․ Current Medical Diagnosis & Treatment: Chapter 16. Liver, Biliary Tract, & Pancreas Disorders, 2. Chronic Hepatitis C, Clinical Findings & Diagnosis (2015) ․ Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 8th ed(2015) ․ 2013년 대한간학회: C형간염 진료 가이드 ․ EASL(European Association for the Study of the Liver) Recommendations on Treatment of Hepatitis C (2015) ․ AASLD-IDSA Recommendations for Testing, Managing, and Treating Adults Infected With Hepatitis C Virus ․ Molina JM, et al. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients c-infected with HIV(PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study. Lancet 2015;385:1098-106. ․ Masao Omata et al. Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial. Journal of Viral Hepatitis 2014;21:762-8. ․ Zeuzem S, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. NEJM 2014 May; 370:1993-2001. ․ Jacobson IM , et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. NEJM 2013 May;368;1867-77. ․ Kwang-Hyub Han, et al. A Phase 3b, Multicenter, Open-Label, Randomized Study to Investigate the Efficacy and Safety of Sofosbuvir plus Ribavirin in Treatment-Naive Subjects with Chronic Genotype 1, 2, 3 and 6 HCV Infection and in Treatment-Experienced Subjects with Chronic Genotype 2 HCV Infection. Study GS-US-334-0115 Interim Clinical Study Report. |
|||||||||||||||||||||||||||||||||
